IN THE MATTER OF the *Patent Act* R.S.C. 1985, c.P-4, as amended

AND IN THE MATTER OF Alexion Pharmaceuticals Inc. (the "Respondent") and the medicine "Soliris"

#### AMENDED NOTICE OF APPEARANCE

TAKE NOTICE THAT Her Majesty the Queen in Right of the Province of British

Columbia, as represented by the Minister of Health ("the Minister of Health for British

Columbia") the Ministers of Health for the Provinces of British Columbia and Manitoba

(collectively, "the Ministers of Health") intends to appear and make representations with respect to this matter on the following basis:

- 1. The Minister of Health for the Province of British Columbia, on its own behalf and on behalf of the Ministers of Health for the Provinces of Ontario, Manitoba and Newfoundland and Labrador (collectively, "the Ministers of Health"), intends to make representations supporting the proposed Orders of the Board on the basis set out by Board Staff in the Statement of Allegations of Board Staff ("the Statement of Allegations"), but requesting that the Board order, pursuant to section 83 of the Patent Act, that:
  - (a) the Respondent reduce the price of Soliris to a price that does not exceed the lowest price for Soliris among all comparator countries; and
  - (b) the Respondent offset cumulative excess revenues that it has received by paying to the federal government an amount equal to the excess revenues the Board estimates that the Respondent has generated from the sale of Soliris at an excessive price, with the Board to use the lowest price for Soliris among all comparator countries as the basis for the calculation.

- 2. The Ministers of Health of Ontario, Manitoba and Newfoundland and Labrador have consented to the Minister of Health for British Columbia making representations on behalf of the Ministers of Health. Attached to this Notice of Appearance as Schedule A is a copy are copies of the consent letters.
- The Ministers of Health intend to rely upon the material facts set out in the Statement of Allegations, and upon the documents noted in the List of Attachments to the Statement of Allegations.
- 4. The Ministers of Health also intend to rely upon the Affidavit of Eric Lun, which will be filed at a later date sworn April 1, 2015 and filed herein, and specifically upon the following facts as stated in the Affidavit of Eric Lun:
  - (a) the process by which provincial governments review medicines such as Soliris for potential reimbursement;
  - (b) the cost of Soliris in comparison to other publicly-funded medicines;
  - (c) the importance of the public list price of a medicine in relation to negotiations

    between provincial governments and suppliers and in relation to other

    reimbursement policies;
  - (d) the recommendations made by the Common Drug Review in relation to the reimbursement of Soliris by provincial governments.
- 5. The Ministers of Health also intend to rely upon the following documents attached as exhibits to the Affidavit of Eric Lun:
  - (a) Canadian Expert Drug Advisory Committee Recommendation on Soliris for Indication of Paroxysmal Nocturnal Hemoglobinuria;

(b) Canadian Drug Expert Committee Recommendation on Soliris for Indication of

Atypical Hemolytic Uremic Syndrome;

(c) Common Drug Review Submission Status summary.

6. The Ministers of Health may also rely upon any documents submitted by a participant to

the hearing, and any affidavits filed in the proceeding.

7. Service of any documents in this proceeding may be effected upon the Ministers of Health

by serving:

Ministry of Justice, Legal Services Branch

PO Box 9280 Stn Prov Govt

1001 Douglas Street

Victoria, BC V8W 9J7

Attention: Sharna Kraitberg

Phone: 250-356-8931 Fax: 250-356-8992

E-mail: sharna.kraitberg@gov.bc.ca

with the Minister of Health for ef-British Columbia consenting to accept service of any

documents in this proceeding on behalf of the Ministers of Health, and the Minister of

Health for ef British Columbia agreeing to distribute any documents served upon the

Minister of Health for ef British Columbia to the Ministers of Health of Ontario, Manitoba

and Newfoundland and Labrador, as required.

8. The Ministers of Health request that participation in the hearing (and other related

meetings) be permissible by teleconference.

DATED at Victoria, British Columbia, this 2nd day of April, 2015.

Original signature redacted

Sharna Kraitberg, Counsel for the Minister of Health for

British Columbia

TO: The Secretary of the Patented Medicine Prices Review Board

Standard Life Centre 333 Laurier Avenue West

**Suite 1400** 

Ottawa, Ontario K1P 1C1

AND TO: Christopher Morris and David Migicovsky

Counsel for Board Staff

Perley-Robertson Hill & McDouglas LLP

340 Albert Street

Suite 1400

Ottawa, ON K1R 7Y6

AND TO: Parul Shah

Legal Counsel PMPRB

Patented Medicine Prices Review Board

Legal Services Branch
Standard Life Centre
333 Laurier Avenue West

**Suite 1400** 

Ottawa, Ontario K1P 1C1

AND TO: Malcolm N. Ruby and Alan West

Counsel for the Respondent

Gowling LaFleur Henderson LLP

1 First Canadian Place

100 King Street West, Suite 1600

Toronto, ON M5X 1G5

IN THE MATTER OF the *Patent Act* R.S.C. 1985, c.P-4, as amended

AND IN THE MATTER OF Alexion Pharmaceuticals Inc. (the "Respondent") and the medicine "Soliris"

### **CONSENT FOR REPRESENTATION**

I, ..., have reviewed the draft Notice of Appearance to be submitted by the Minister of Health of British Columbia in the Patented Medicine Prices Review Board Hearing (the "Hearing") related to the pricing of the drug product "Soliris".

I hereby consent to the Minister of Health for British Columbia making representations to the Hearing on behalf of the Minister of Health for the Province of Ontario.

DATED at 105 octo, this 13 day of March, 2015.

MINISTER OF HEALTH FOR THE PROVINCE OF ONTARIO

Original signature redacted

TO:

The Secretary of the Patented Medicine Prices Review Board Standard Life Centre 333 Laurier Avenue West Suite 1400

Ottawa, Ontario K1P 1C1

IN THE MATTER OF the Patent Act R.S.C. 1985, c.P-4, as amended

AND IN THE MATTER OF Alexion Pharmaceuticals Inc. (the "Respondent") and the medicine "Soliris"

# **CONSENT FOR REPRESENTATION**

I. Shand Body, have reviewed the draft Notice of Appearance to be submitted by the Minister of Health of British Columbia in the Patented Medicine Prices Review Board Hearing (the "Hearing") related to the pricing of the drug product "Soliris".

I hereby consent to the Minister of Health for British Columbia making representations to the Hearing on behalf of the Minister of Health for the Province of Manitoba.

DATED at  $\frac{1.56 \, pm}{1.56 \, pm}$ , this  $\frac{5m}{1.50 \, pm}$  day of March, 2015.

MINISTER OF HEALTH FOR THE PROVINCE OF MANITOBA

Original signature redacted

TO:

The Secretary of the Patented Medicine Prices Review Board Standard Life Centre 333 Laurier Avenue West Suite 1400 Ottawa, Ontario K1P 1C1

IN THE MATTER OF the Patent Act R.S.C. 1985, c.P-4, as amended

AND IN THE MATTER OF Alexion Pharmaceuticals Inc. (the "Respondent") and the medicine "Soliris"

#### CONSENT FOR REPRESENTATION

I, <u>Bruce Cooper</u>, have reviewed the draft Notice of Appearance to be submitted by the Minister of Health of British Columbia in the Patented Medicine Prices Review Board Hearing (the "Hearing") related to the pricing of the drug product "Soliris".

I hereby consent to the Minister of Health for British Columbia making representations to the Hearing on behalf of the Minister of Health and Community Services for the Province of Newfoundland and Labrador.

DATED at St. John's in the province of Newfoundland and Labrador this  $\frac{q^{th}}{}$  day of March, 2015.

MINISTER OF HEALTH AND COMMUNITY SERVICES FOR THE PROVINCE OF NEWFOLINDLAND AND LABRADOR

Original signature redacted
Minister or authorized designate

TO:

The Secretary of the Patented Medicine Prices Review Board Standard Life Centre 333 Laurier Avenue West Suite 1400 Ottawa, Ontario K1P 1C1